Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxycarbamide - Addmedica

Drug Profile

Hydroxycarbamide - Addmedica

Alternative Names: Hydroxyurea - Addmedica; NSC-32065; Onco-carbide; Siklos; SQ-1089

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProStrakan
  • Developer addmedica; Medunik USA
  • Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action DNA synthesis inhibitors; Fetal haemoglobin stimulants; Nitric oxide stimulants; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sickle cell anaemia

Most Recent Events

  • 28 May 2019 Addmedica initiates the phase II SIKAMIC trial in Sickle cell anaemia in France (NCT03806452)
  • 16 Jan 2019 Addmedica plans the SIKAMIC phase II trial for Sickle cell disease in February 2019 (NCT03806452)
  • 19 Nov 2018 Launched for Sickle cell anaemia (In adolescents, In children, In adults) in USA (PO, 1000mg triple scored tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top